NCT02465060 2026-04-13Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)National Cancer Institute (NCI)Phase 2 Active not recruiting6,452 enrolled 2 FDA
NCT04099251 2026-04-09CheckMate76KBristol-Myers SquibbPhase 3 Active not recruiting790 enrolled 18 charts 2 FDA
NCT03969004 2026-03-27Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell CarcinomaRegeneron PharmaceuticalsPhase 3 Active not recruiting415 enrolled 2 FDA
NCT03070392 2026-03-17Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal MelanomaImmunocore LtdPhase 2 Completed378 enrolled 15 charts 2 FDA
NCT02362594 2026-03-05MK-3475-054Merck Sharp & Dohme LLCPhase 3 Active not recruiting1,019 enrolled 16 charts 1 FDA
NCT03470922 2025-09-09RELATIVITY-047Bristol-Myers SquibbPhase 2/3 Active not recruiting714 enrolled 17 charts 2 FDA
NCT03599713 2025-08-05A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)Incyte CorporationPhase 2 Completed107 enrolled 16 charts 2 FDA
NCT02908672 2025-07-20A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced MelanomaHoffmann-La RochePhase 3 Completed514 enrolled 25 charts 1 FDA